Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

surveys show — and now a major new study has revealed a long list of benefits and some little-known risks. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...